Table 1.
Clinical description of prostate cancer cases diagnosed in Mallorca between 2006–2011 (N = 2921).
| Variable | Categories | Number | % | % Valid | After MI |
|---|---|---|---|---|---|
| Age | 15–54 | 163 | 5.6 | 5.6 | |
| 55–64 | 817 | 28.0 | 28.0 | ||
| 65–74 | 1221 | 41.8 | 41.8 | ||
| 75–84 | 598 | 20.5 | 20.5 | ||
| 85 or + | 122 | 4.2 | 4.2 | ||
| Histology | Adenocarcinoma | 2710 | 92.8 | 92.8 | |
| Unspecified | 161 | 5.5 | 5.5 | ||
| Other | 50 | 1.7 | 1.7 | ||
| T_PT | 1 | 599 | 20.5 | 34.5 | |
| 2 | 756 | 25.9 | 43.5 | ||
| 3 | 355 | 12.2 | 20.4 | ||
| 4 | 27 | 0.9 | 1.6 | ||
| Missing | 1184 | 40.5 | |||
| N_PN | 0 | 1214 | 41.6 | 95.2 | |
| 1 | 61 | 2.1 | 4.8 | ||
| Missing | 1646 | 56.4 | |||
| M | 0 | 1908 | 65.3 | 90.9 | |
| 1 | 190 | 6.5 | 9.1 | ||
| Missing | 823 | 28.2 | |||
| Stage | I | 454 | 15.5 | 33.7 | |
| II | 438 | 15.0 | 32.5 | ||
| III | 216 | 7.4 | 16.0 | ||
| IV | 240 | 8.2 | 17.8 | ||
| Missing | 1573 | 53.9 | |||
| PSA | ≤10 | 1025 | 35.1 | 59.4 | |
| 11–20 | 306 | 10.5 | 17.7 | ||
| >20 | 395 | 13.5 | 22.9 | ||
| Missing | 1195 | 40.9 | |||
| Gleason | 4 | 34 | 1.2 | 1.5 | |
| 5 | 134 | 4.6 | 5.8 | ||
| 6 | 937 | 32.1 | 40.5 | ||
| 7 (3 + 4) | 615 | 21.1 | 26.6 | ||
| 7 (4 + 3) | 273 | 9.3 | 11.8 | ||
| 8 | 166 | 5.7 | 7.2 | ||
| 9 | 143 | 4.9 | 6.2 | ||
| 10 | 13 | 0.4 | 0.6 | ||
| Missing | 606 | 20.7 | |||
| Risk | Low | 189 | 6.5 | 8.6 | 9.5 |
| Medium | 512 | 17.5 | 23.2 | 24.9 | |
| High | 971 | 33.2 | 44.0 | 42.7 | |
| Very high | 533 | 18.2 | 24.2 | 22.9 | |
| Missing | 716 | 24.5 | |||
| Charlson index | 0 | 1745 | 59.7 | 59.7 | |
| 1 | 694 | 23.8 | 23.8 | ||
| 2 | 295 | 10.1 | 10.1 | ||
| ≥3 | 187 | 6.4 | 6.4 | ||
| Treatment | Local | 1478 | 50.6 | 50.6 | |
| Systemic | 642 | 22.0 | 22.0 | ||
| Mixed | 231 | 7.9 | 7.9 | ||
| Observation/unspecified | 570 | 19.5 | 19.5 | ||
| Vital status | Alive | 2244 | 76.8 | 76.8 | |
| Death from prostate cancer | 324 | 11.1 | 11.1 | ||
| Death from other causes | 349 | 12.0 | 12.0 | ||
| Missing | 4 | 0.1 |